



**Provided for non-commercial research and education
use.**



Egyptian Academic Journal of Biological Sciences is the official English language journal of the Egyptian Society of Biological Sciences, Department of Entomology, Faculty of Sciences Ain Shams University.

The Journal publishes original research papers and reviews from any zoological discipline or from directly allied fields in ecology, behavioral biology, physiology & biochemistry.

www.eajbs.eg.net



Ameliorative Role of Lactoferrin on Osteoporosis Caused by Glucocorticoids

Rana A. Ali and Ghada, A. Mubark

Department of Zoology, Faculty of Science, South Valley University, Qena,
Egypt

E.Mail : rana.ahmed@sci.svu.edu.eg

ARTICLE INFO

Article History

Received:5/3/2019

Accepted:29/3/2019

Keywords:

Glucocorticoids,
Osteoporosis,
Lactoferrin,
Calcium,
Testosterone
Hormone, PTH,
bone density, rats.

ABSTRACT

Lactoferrin is derived from its past classification as a major iron-binding protein in milk, which was in bovine milk. Osteoporosis is a major disease affecting human bone. Which is caused by endocrinological disorders and drugs Glucocorticoids – induced osteoporosis is the most common form of secondary osteoporosis. The current study was aimed to study the curative role of natural substances (lactoferrin) on the osteoporosis caused by glucocorticoids (prednisone) and comparing its curative effect with sodium alendronate the common therapy for osteoporosis. Our experiment included 8 groups in each group 10 adult's albino rats 4 groups male or the other groups are female. First group (normal females) and fifth group (normal males) were given saline for two months. Second group (control females) and sixth group (control males) were given prednisone orally (25mg/kg b. w.) day after day for two months. Third group (treated females) and seventh group (treated males) were given (25mg/ kg b.w.) day after day for two months and then lactoferrin (0.85 mg/kg body weight) daily for two months. Fourth group (treated females) and eighth group (treated males) were given (25mg/ kg b.w.) day after day for two months and then sodium alendronate (300 µg/kg b.w.) once weekly for two months. After treatment, blood samples were collected for estimating calcium, phosphorous, PTH and testosterone levels in serum. Right femur bones were removed for determining the density, calcium and phosphorous content. The results indicated that lactoferrin and prednisone were increased serum calcium and PTH levels $P < (0.05)$, in males and females animals and decreased serum phosphorous for the two sexes, but for testosterone there was a non-significant decrease for female animals and a significant decrease for male animals. Administration of lactoferrin was ameliorated the disturbances of bone. The result suggests that lactoferrin may improve prednisone - induced osteoporosis.

INTRODUCTION

Bone is a connective tissue that is undergoing continual remodeling. Bone remodeling involves osteoblast formation of the bone and osteoclasts resorption of the bone. With regular resorption and deposition of Ca in freshly deposited bone, bone undergoes continuous remodeling.. Osteoporosis is a skeleton's chronic, systemic, metabolic disease characterised by reduced bone mass, architectural defects and reduced mechanical resistance to injury, resulting in accumulated risk of fracture.(Kaczmarek *et al.*, 2004). Milk is a rich biological fluid containing several

growth sources and providing nutrition within the babe at a time of terribly rapid growth and development of the skeleton, thus being thought of potential supply of factors with anabolic effects on the bone. Lactoferrin was identified as a bone - active factor by investigations of fractions of whey proteins extracted from milk. It is a pleiotropic factor with powerful antimicrobial and immunomodulatory activities and shows physiological anabolic effects in the bone (Dorit et al., 2012). Additional dietary lactoferrin has improved bone mineral density, bone markers, and bone strength in a number of recent studies in humans and experimental animals. The current study discusses the bone health improvement effect of lactoferrin. Osteoporosis is considered a major public health problem and is characterized by reduced bone density resulting in fragility and fractures of the skeleton (McCarron and Heaney, 2004). Osteoporosis is three times more common in women than in men, partly because of the hormonal changes that occur at the menopause. Osteoporosis has also adversely affected elderly patients' quality of life. There are two types of osteoporosis: primary osteoporosis resulting from aging and menopause, secondary osteoporosis resulting from certain drugs as a side effect. Glucocorticoid administration resulted in the most common secondary osteoporosis. Glucocorticoids are a class of steroid hormones found in nearly every animal cell and play a key role in a wide range of physiological responses. (Rhen and Cidlowski, 2005). Due to their powerful anti - inflammatory and immunosuppressive effects, synthetic glucocorticoids called corticosteroids (e.g. prednisone) have been widely used as a therapeutic option in pharmacology for a wide range of autoimmune and inflammatory diseases (Barnes, 2006). However, the benefits derived from the use of corticosteroids may be offset by the under occurrence of corticosteroid-related osteoporosis. American College of Rheumatology reported that glucocorticoid medicines have both direct and indirect effects on bone tissue that lead to bone loss. These drugs have a direct negative effect on bone cells, leading to a lower rate of new bone formation. They can also interfere with calcium handling by the body and affect sex hormone levels. Either of these issues may result in increased loss of bone. Long administration of glucocorticoid causes osteoporosis (Mazziotti et al., 2006). Glucocorticoids disturb calcium metabolism. They can also interfere with calcium handling by the body and affect sex hormone levels. Either of these issues may result in increased loss of bone. (Mazziotti et al., 2006). These actions may theoretically lead to a secondary increase in parathyroid hormone concentrations (Rubin and Bilezikian, 2002). These changes can have negative effects on bone metabolism (Mazziotti et al., 2006).

Glucocorticoid reduce production of steroid by gonadal. Low serum testosterone levels have been stated in glucocorticoid-treated men and may be due to both direct effects on the testis and indirect effects on testosterone production mediated due to destruction of gonadotropin hormone secretion (Mateo et al., 1995). glucocorticoids may have a direct effect on the renal handling of this mineral. They may also directly inhibit gastrointestinal absorption of phosphate (Cosman et al., 1994). Long-term treatment with glucocorticoids reduces bone mineral density leading to osteoporosis (Reid, 1997).

We found that a variety of fractions of whey protein extracted from milk have growth stimulatory effects in primary cultures of osteoblasts. High-performance liquid action analysis of the main proteins within the active fractions known the presence of the glycoprotein lactoferrin in most of those fractions (Naotet *al.*, 2005).

Lactoferrin is a glycoprotein found in milk (Masson and Heremans, 1971 and Brock, 1980) It is structurally the same as transferrin it's terribly plentiful in colostrum and little amounts may also be found in tears, saliva, within the secondary

granules of neutrophils. and most mucosal secretions like uterine fluid, vaginal secretion, semen, digestive fluid, bile and bowel secretions, (Kikuchi *et al.*, 2003 and Baker and Baker, 2005). It made with the aid of mucosal epithelium and neutrophils and is released through these cells in reaction to inflammatory stimuli.

Bisphosphonates were evolved and used in the treatment of bone diseases, more often than not Paget's disease, hypercalcemia of malignancy, and recently, osteoporosis. WHO changed into stated that bisphosphonate is the choice for osteoporosis. Alendronate is considered one of bisphosphonate organization and has an extra bone affinity. The endorsed weekly dose of alendronate at 70 mg is nearly double the potency of the encouraged dose of 35 mg rise Alendronate (Cheng *et al.*, 2009).

MATERIALS AND METHODS

Material:

Animals: 80 adult albino rats (male and female) at age (2-3 month) and weight about (180-200 g) were obtained from the Animal House, Faculty of Science, South Valley University, Qena, Egypt.). They were kept under standard conditions of temperature ($23\pm 2^{\circ}\text{C}$), and 12h light/dark period, and fed with a standard pellet diet and water. The animals have divided into 8 groups each group contain 10 rats male or female (4 groups female and 4 groups male)

Drugs and Chemicals:

A-Prednisone (Hostacortine):

Hostacortine tablets 5 mg from Sanofi Aventis Egypt.

B-Lactoferrin:

Lactoferrin is an iron-binding protein. It extracted from human milk. It brought from the sigma Aldrich Company as a powder.

C-Fosamax (Sodium alendronate 70 mg tablets):

It was obtained from MSD. Which is described chemically as: (4-amino-1-hydroxybutylidene) bisphosphonic acid monosodium salt trihydrate.

Experimental design:

The experimental animals were classified into 8 groups, 10 rats of each group.

G1 (normal female group): this group was given only NaCl 0.9% and sacrificed after 2 months.

G2 (control female group): received prednisone (25 mg/kg body weight) (Jacobs *et al.*, 1996) day after day orally for 2 months.

G3 (treated female group): received prednisone (25 mg/kg body weight) day after day orally for 2 months and then lactoferrin (0.85 mg/kg body weight) (Guo *et al.*, 2009) daily for 2 months.

G4 (treated female group): received prednisone (25 mg/kg body weight) day after day orally for 2 months and then sodium alendronate (300 $\mu\text{g/kg}$ body weight/week) (Lee *et al.*, 2006).

G5 (normal male group): this group was given only NaCl 0.9%.

G6 (control male group): received prednisone (25 mg/kg body weight) day after day orally for 2 months.

G7 (treated male group): received prednisone (25 mg/kg body weight) day after day orally for 2 months and then lactoferrin (0.85 mg/kg body weight) daily for 2 months.

G8 (treated group): received prednisone (25 mg/kg body weight) day after day orally, for 2 months and then sodium alendronate 300 $\mu\text{g/kg}$ body weight/week.

At the end of experiment, the animals were sacrificed by decapitation. Blood samples of all animals prepared from retro-orbital eye vein. Samples were collected in clean tubes at room temperature to clot then after an hour; serum was separated by centrifugation for 30 minutes at 3000 rpm. The serum was collected in labeled Eppendorf tubes and stored at -20 °C until used for biochemical analysis. Right femurs were removed, frozen at -20 °C until analysis.

Methods:

biochemical Analysis:

Calcium was estimated in serum by commercially available kit from randox company using the colorimetric method according to (Cooper, 2013) by using 5010 spectrophotometers (semi-automatic). Phosphorous was estimated in serum by commercially available kit from GPL company using a colorimetric method according to (Farrell and Kaplan, 1984), by using 5010 spectrophotometers (semi-automatic). Parathyroid Hormone (PTH) was estimated in serum by a commercially available ELISA kit from Sigma Aldrich company by using (Bieglmayer et al., 2002) method. Testosterone Hormone was estimated in serum by a commercially available ELISA kit from sigma Aldrich company (Nobert, 1995).

Bone Density:

The density of the femur was calculated from the mass in the air and in water by Archimedes principle (Kalu et al., 1984)

Preparation of Bone Solution:

- 1-Right femurs were manually cleaned from adhering soft tissue.
- 2-determine the volume.
- 3-dried 18 h at 100 °C and weighed.
- 4-digested overnight in 5ml of 60% HNO₃ by use of a modification of the method of (Brown et al. 1976).
- 5-the digests were heated to 80 °C, and after the addition of 0.3 ml 30% H₂O₂, filtered through What man filter paper.
- 6-Calcium and phosphorous concentrations were determined on the digested bone solution using spectrophotometry as the same methods of serum calcium and phosphorus.

Statistical analysis:

The varying degree of results was expressed as a Means S.D. The data were statistically analyzed by one-way ANOVA analysis of variance (prism computer program, year) and the least significant difference (L.S.D) was used to test the difference between treatments. The results were considered statistically significant when $P < (0.05)$.

RESULTS

1-Serum Calcium and Phosphorous:

The effect of prednisone (25 mg /kg b.wt.) alone and the effect of lactoferrin(0.85 mg/kg b.w.) and sodium alendronate (300 µg/kg b.w./week) on serum calcium and phosphorous in female and male albino rats post-treated with prednisone:

In prednisone-treated female and male animals a significant increase in serum calcium level and a significant decrease in serum phosphorous when compared with normal animals at ($p < 0.05$). Lactoferrin and sodium alendronate treated animals showed a significant decrease in calcium level and a significant increase in phosphorous when compared with the control group, calcium and phosphorous levels returned to the normal values in female and male animals when compared with normal (Tables 1 & 2) respectively.

Table (1): Effect of lactoferrin and sodium alendronate on serum calcium and phosphorous after prednisone treatment on female animals.

Group \ Parameter	Serum calcium mg/dl M.± S.D.	Serum phosphorous mg/dl M.± S.D.
G1 (normal females)	7.59± 0.96	5.81 ± 0.81
G2 (prednisone)	10.89 ± 0.99 ^{+a}	3.83 ± 0.81 ^{-a}
G3 (prednisone + lactoferrin)	6.99 ± 0.96 ^{-b}	5.30 ± 0.81 ^{+b}
G4 (prednisone + alendronate)	7.36 ± 0.70 ^{-b}	5.76 ± 0.81 ^{+b}

The result presented the mean ± S.D. Of 10 rats.

- + significant increase at (p<0.05). a → significantly different from normal rats.
 – significant decrease at (p<0.05). b → significantly different from control rats

Table (2): Effect of lactoferrin and sodium alendronate on serum calcium and phosphorous after prednisone treatment on male animals.

Group \ Parameter	Serum calcium mg/dl M.± S.D.	Serum phosphorous mg/dl M.± S.D.
G5 (normal males)	9.44 ± 0.52	5.40 ± 0.88
G6 (prednisone)	11.54 ± 1.38 ^{+a}	4.73 ± 0.64 ^{-a}
G7 (prednisone + lactoferrin)	9.27 ± 0.68 ^{-b}	5.19 ± 0.31 ^{+b}
G8 (prednisone + alendronate)	8.86 ± 0.59 ^{-b}	5.37 ± 0.41 ^{+b}

The result presented the mean ± S.D. Of 10 rats.

- + significant increase at (p<0.05). a → significantly different from normal rats.
 – significant decrease at (p<0.05). b → significantly different from control rats.

2-Serum PTH and Testosterone:

The effect of prednisone (25 mg /kg b.wt.) alone and the effect of lactoferrin(0.85 mg/kg b.w.) and sodium alendronate (300 µg/kg b.w./week)on PTH and testosterone in female and male albino rats post-treated with prednisone:

in prednisone-treated female and male animals a significant increase in PTH when compared with normal animals at (p<0.05). lactoferrin and sodium alendronate treated groups showed a significant decrease in PTH when compared with the control group, PTH returned to the normal values in female and male animals. While there is a non-significance decrease in testosterone level in females animals treated with prednisone also lactoferrin and sodium alendronate treated groups showed an insignificant decrease in testosterone level but in male rats treated with prednisone showed a significant decrease in testosterone level but lactoferrin and sodium alendronate treated groups showed a significant increase in testosterone level when compared with the control group but still lower than the normal group when compared with normal rats.(Tables 3 & 4).

Table (3): Effect of lactoferrin and sodium alendronate on PTH and testosterone after prednisone treatment of females animals.

Group \ Parameter	PTH (Pg/ml) M. $\pm$ S.D.	Testosterone (ng/ml) M. $\pm$ S.D.
G1 (normal females)	3.61 $\pm$ 0.25	0.12 $\pm$ 0.05
G2 (prednisone)	4.06 $\pm$ 0.17 ^{+a}	0.09 $\pm$ 0.01
G3 (prednisone + lactoferrin)	3.37 $\pm$ 0.21 ^{-b}	0.12 $\pm$ 0.06
G4 (prednisone + alendronate)	3.39 $\pm$ 0.21 ^{-b}	0.12 $\pm$ 0.06

The result presented the mean $\pm$ S.D. Of 10 rats.

- + significant increase at (p<0.05).a $\rightarrow$ significantly different from normal rats.
- significant decrease at (p<0.05). b $\rightarrow$ significantly different from control rats.

Table (4): Effect of lactoferrin and sodium alendronate on PTH and testosterone after prednisone treatment on male animals.

Group \ Parameter	PTH (Pg/ml) M. $\pm$ S.D.	Testosterone (ng/ml) M. $\pm$ S.D.
G5 (normal males)	3.46 $\pm$ 0.28	5.41 $\pm$ 0.32
G6 (prednisone treated males)	4.59 $\pm$ 0.23 ^{+a}	4.14 $\pm$ 0.21 ^{-a}
G7 (prednisone + lactoferrin)	3.41 $\pm$ 0.16 ^{-b}	5.06 $\pm$ 0.13 ^{-a +b}
G8(prednisone + alendronate)	3.46 $\pm$ 0.22 ^{-b}	4.93 $\pm$ 0.21 ^{-a +b}

The result presented the mean $\pm$ S.D. Of 10 rats.

- + significant increase at (p<0.05).a $\rightarrow$ significantly different from normal rats.
- significant decrease at (p<0.05). b $\rightarrow$ significantly different from control rats.

3-Bone Calcium, Phosphorous and Density:

The effect of prednisone (25 mg /kg b.wt.) alone and the effect of lactoferrin (0.85 mg/kg b.w.) and sodium alendronate (300 μ g/kg b.w./week) on bone calcium, phosphorous and density in female and male albino rats post-treated with prednisone:

In prednisone-treated female and male animals there is a significant decrease in bone density, calcium and phosphorous contents when compared with normal rats. lactoferrin and alendronate ameliorated these disturbances where the results in table 5&6 indicated that the bone density, calcium and phosphorous contents increased significantly when compared with control group, which return to the normal values in female and male animals when compared with normal rats. (Tables 5 & 6).

Table (5): Effect of lactoferrin and sodium alendronate on femur calcium, phosphorous and density after prednisone treatment of females animals.

Group \ Parameter	Femur density (g/cm ³) M. ± S.D.	Femur calcium content(mg/dl) M. ± S.D.	Femur phosphorous content(mg/dl) M. ± S.D.
G1 (normal females)	0.524 ± 0.038	337.1 ± 3.436	123.1 ± 3.976
G2 (prednisone)	0.406 ± 0.094 ^{-a}	326.3 ± 3.49 ^{-a}	110.3 ± 4.99 ^{-a}
G3 (prednisone +lactoferrin)	0.546 ± 0.036 ^{+b}	339.4 ± 3.21 ^{+b}	129.1 ± 4.45 ^{+b}
G4(prednisone +alendronate)	0.533 ± 0.0467 ^{+b}	337.4 ± 4.12 ^{+b}	127.4 ± 4.86 ^{+b}

The result presented the mean ± S.D. Of 10 rats.

+ significant increase at (p<0.05). a → significantly different from normal rats.

– significant decrease at (p<0.05). b → significantly different from control rats.

Table (6): Effect of lactoferrin and sodium alendronate on femur calcium, phosphorous and density after prednisone treatment of males animals

Group \ Parameter	Femur density (g/cm ³) M. ± S.D.	Femur calcium content(mg/dl) M. ± S.D.	Femur phosphorous content(mg/dl) M. ± S.D.
G5 (normal males)	0.541 ± 0.07	340.1 ± 3.29	126.6 ± 2.94
G6 (prednisone)	0.472 ± 0.027 ^{-a}	326.6 ± 3.21 ^{-a}	114.9 ± 1.95 ^{-a}
G7 (prednisone +lactoferrin)	0.573 ± 0.02 ^{+b}	338.6 ± 3.59 ^{+b}	127.4 ± 3.21 ^{+b}
G8 (prednisone + alendronate)	0.583 ± 0.037 ^{+b}	338.1 ± 1.68 ^{+b}	126.6 ± 1.90 ^{+b}

The result presented the mean ± S.D. Of 10 rats.

+ significant increase at (p<0.05). a → significantly different from normal rats.

– significant decrease at (p<0.05). b → significantly different from control rats.

DISCUSSION

Plenty of attention has currently been targeted at the role and mechanism of motion of clearly happening compounds in the biological system as an example on bone osteoporosis.

Lactoferrin has powerful anabolic as well as potent inhibitory bone resorption properties and may increase bone formation in vivo (Cornish *et al.*, 2004). In the current study, we have to compare the effect of lactoferrin on secondary osteoporosis caused by glucocorticoids (prednisone) with the effect of alendronate which belong to Bisphosphonates where The most common cause of secondary osteoporosis is glucocorticoid is prolonged high - dose glucocorticoid therapy (Ilona *et al.*, 2012). In the present work, we have to study the effect of Lactoferrin and alendronate on osteoporosis induced by glucocorticoid (prednisone) in females and males rats. From obtained results, we noticed the glucocorticoid caused the increase in serum calcium and the decrease in serum phosphorous levels, the similar result was obtained by (Elshal *et al.*, 2013) showed that serum phosphorus concentration was significantly lower in glucocorticoid administration. On the other hand (Shomali and Fakhrzad, 2013) recorded in their study on rats an insignificant increase in calcium level in rats that treated with glucocorticoid. Also, Yonemura *et al.*, (1999) Stated that the oral dose of prednisolone administration increases serum calcium and ionized calcium levels, possibly mediated by suppressed bone formation, increased calcium absorption in the intestine, and impaired calcium excretion in the urine. Also, an increase of serum

calcium after glucocorticoid administration might occur as a result of increased release of Calcium from bone tissues (Elshal et al., 2013).

Hypercalcaemia differential is wide and can be categorized on the basis of levels of parathyroid hormone (PTH). PTH is secreted by the parathyroid glands. A unique calcium receptor (extracellular calcium - sensing receptor) on the parathyroid cell membrane quickly responds to changes in plasma calcium levels (Ayuk *et al.* 2010). Appropriate inhibition of PTH release should occur when the plasma calcium level is high. In the pathophysiology of hypercalcaemia, at least one of the following mechanisms is involved: (1) increased intestinal calcium absorption; (2) increased bone resorption ; and (3) increased renal calcium reabsorption or reduced calcium excretion. Hypercalcaemia results mainly from the increased mobilization of calcium from the bone through the final common activation pathway of RANK (receptor activator of nuclear factor - kappa B) receptors on the osteoclastic surface by RANK - ligand (RANKL) derived from osteoblasts, (Tanaka *et al.*, 2005). Drugs used to treat dyspepsia or more commonly now osteoporosis can lead to hypercalcaemia mediated by high calcium intake plus metabolic alkalosis, which increases the reabsorption of calcium in the distal tubule. Hypercalcaemia is well known but rare in the context of vitamin D intoxication (Holick, 2007). The present study showed the glucocorticoid caused a significant elevate in parathyroid hormone level in both sexes but for androgen (testosterone) level the study was showed a significant decrease in the male rats, but there was an insignificant decrease in testosterone level of female rats. Several studies have found increased levels of PTH and excretion of urinary calcium. One of them suggests a vitamin D deficiency (Cosman et al., 1994) may contribute to reduced calcium absorption and increased PTH secretion. A direct effect of glucocorticoid on PTH's glandular secretion may also contribute to high PTH serum levels (Fucik et al., 1975). But as a result of these effects, glucocorticoid use could result in secondary hyperparathyroidism. However, a hyperparathyroidism state does not explain the bone disorder observed in Glucocorticoid-induced osteoporosis.

Gonadal hormone reduction is an important mechanism through glucocorticoid inhibitory effects on pituitary gonadotropins (Lane and Lukert, 1998). In men, glucocorticoids can inhibit testosterone production through the suppression of gonadotropin hormone secretion due to direct effects on the testis and indirect effects (Luiz *et al.*, 2006). Low levels of serum testosterone can help lower osteoblastic activation. Glucocorticoids blunt LH secretion in males and females in response to GnRH (Sakakura et al., 1975 and Luton et al., 1977). In the previous study, asthmatic men treated with prednisone at an average daily dose of 12 mg had significantly lower free and total testosterone levels than age-matched control subjects (Reid et al., 1985). Dolatabadi and Zarchii, (2015) stated that the testosterone level in male rats receiving glucocorticoid was shown to be lower compared to the control group. Gao et al., (2003) showed in their study that increase in the concentration of serum glucocorticoids due to stress caused controlling activity of testosterone making enzymes and reduction in leydig cells, then testosterone secreting would reduce. In a similar study corticosteroid, administration caused a suppression in androgen level in female rats (Brann and Mahesh, 1991).

While bone density, calcium and phosphorous femur contents showed a significant decrease in females and males rats treated by the glucocorticoid.

A significant decrease in the level of phosphorus content of femur bone was observed in the lowest dose of prednisone treatment level (Lin et al., 2014), these results agree with our result. The data of the present study also agree with (Ima and Fakhrurazi, 2002) who founded that the administration of dexamethasone (120 µg/kg

body wt.) caused a decrease in femur calcium content. And (Thakur et al., 2013) who indicated that the administration of glucocorticoids caused a decrease in femur density. Hyperparathyroidism that can cause calcium changes associated with a compensatory increase in PTH resulting in the release of calcium from the skeleton resulting in the bone loss (Guillemant et al., 1999).

The present study showed that the lactoferrin improved the disturbances of serum (calcium, phosphorous, parathyroid hormone and testosterone) in both sexes that prednisone caused, also the lactoferrin improved the femur density, calcium and phosphorous values and became near to normal animals. The mechanisms of action of lactoferrin on bone cells also require further investigation as the pathways through which lactoferrin acts to inhibit osteoclastogenesis are largely unknown (Dorit et al., 2005). Cornish et al. (2004) showed the first evidence in their study that lactoferrin promotes osteoblast growth. It also shows that lactoferrin is osteoclastogenesis in vitro inhibitor and increases in vivo local bone formation. The physiological role of lactoferrin in the development of the skeleton or homeostasis (Dorit et al., 2005). Lactoferrin is expressed within the embryo and will play a job in the development and performance of chondrocytes and osteoblasts in the fetal skeleton (Dorit et al., 2005).

Sayed *et al.*, (2013) suggested that the alendronate treatments were found to help in restoring the tibia phosphorous and calcium content in ovariectomized rats near to the normal rats, also alendronate decreased PTH level increase serum phosphorus level and increased bone mineral density in the same study and this agreement with our result. In an agreement with our study Sass *et al.*, (1997) Alendronate treatment reported a reduction in osteocalcin by day 28 and a marginal decrease in total serum calcium. Bisphosphonates (alendronate) induce apoptosis of osteoclasts and inhibit bone resorption (Frith et al., 1997). Randomized clinical trials showed that treatment with bisphosphonates prevents corticosteroid-induced bone loss. Alendronate, a member of the bisphosphonate family, is positive in the prevention and therapy of glucocorticoid-induced osteoporosis and has been stated to inhibit bone loss and enhance the Bone mineral density of lumbar vertebrae by way of decreasing each bone formation and resorption and suppressing bone metabolism.

Conclusion

The present study indicated that lactoferrin as a natural product has a curative effect on osteoporosis caused by prednisone drug as well as the alendronate drug.

REFERENCES

- Ayuk, J.; Cooper, M. S., and Gittoes, N. J. (2010). New perspectives in the management of primary hyperparathyroidism. *Ther. Adv. Endocrin. and Metab.*, 1(5): 197-205.
- Baker E. N. and Baker H. M. (2005): Molecular structure, binding properties and dynamics of lactoferrin. *Cell Mol. Life Sci.*, 62(22): 2531–2539.
- Barnes P. J. (2006): Corticosteroid effects on cell signalling. *Eur. Respir. J.*, 27(2): 413–426.
- Bieglmayer C.; Prager G. and Niederle B. (2002): Kinetic analyses of parathyroid hormone clearance as measured by three rapid immunoassays during parathyroidectomy. *Clin. Chem.*, 48(10): 1731–1738.
- Brann D. W. and Mahesh V. B. (1991): Role of corticosteroids in female reproduction. *FASEB. J.*, 5(12): 2691–2698.
- Brock J. H. (1980): Lactoferrin in human milk: its role in iron absorption and

- protection against enteric infection in the newborn infant. *Arch. Dis. Child.*, 55(6): 417.
- Brown E. D.; Chan W. and Smith Jr. J. C. (1976): Vitamin A metabolism during the repletion of zinc deficient rats. *J. nut.*, 106(4): 563–568.
- Cheng A.; Daly C. G.; Logan R. M.; Stein B. and Goss A. N. (2009): Alveolar bone and the bisphosphonates. *Aust. Dent. J.*, 54: 51–61.
- Cooper G. R. (2013): *Standard Methods of Clinical Chemistry: By the American Association of Clinical Chemists*. 1stEd. Academic Press., 7: 143–150.
- Cornish J.; Callon K. E.; Naot D.; Palmano K. P.; Banovic T.; Bava U.; Watson M.; Lin J. M.; Tong P. C. and Chen Q. et al. (2004): Lactoferrin is a potent regulator of bone cell activity and increases bone formation in vivo. *Endocrinology*, 145(9): 4366–4374.
- Cosman F.; Nieves J.; Herbert J.; Shen V. and Lindsay R. (1994): High-dose glucocorticoids in multiple sclerosis patients exert direct effects on the kidney and skeleton. *J. Bone Miner. Res.*, 9(7): 1097–1105.
- Dorit N.; Andrew G.; Ian R. R. and Jillian C. (2005): Lactoferrin – A Novel Bone Growth Factor. *Clinical Medicine & Research*, 3(2): 93–101.
- Dorit, N.; Kate, P. and Jillian, C. (2012): Lactoferrin – A Potential Anabolic Intervention in Osteoporosis. 24thEd. *Osteoporosis*, 803–821.
- Dolatabadi A. A. and Zarchii S. R. (2015): The effect of prescription of different Dexamethasone doses on reproductive system. *Biomed. Res.*, 26(4): 656–660.
- Elshal M. F.; Almalki A. L.; Hussein H. K. and Khan J. A. (2013): Synergistic antiosteoporotic effect of *Lepidium sativum* and alendronate in glucocorticoid-induced osteoporosis in Wistar rats. *African J. Tradit. Complement Altern. Med.*, 10(5): 267–273.
- Farrell E. C.; Kaplan A. (1984): *Phosphorus in clinical chemistry. theory, analysis and correlation*. CV Mosby Co., 1072–1074.
- Frith J. C.; Mönkkönen J.; Blackburn G. M.; Russell R. G. G. and Rogers M. J. (1997): Clodronate and Liposome-Encapsulated Clodronate Are Metabolized to a Toxic ATP Analog, Adenosine 5 (β,γ -Dichloromethylene) Triphosphate, by Mammalian Cells In Vitro. *J. Bone Miner. Res.*, 12(1): 1358–1367.
- Fucik R.F.; Kukrejas S.C.; Hargis G.K.; Bowser E.N.; Henderson W.J. and Williams GA. (1975): Effect of glucocorticoids on function of parathyroid glands in man. *J. Clin. Endocrinol. Metab.*, 40:152–155.
- Gao H. B.; Tong M. H.; Hu Y. Q.; You H. Y.; Guo Q. S.; Ge R. S. and Hardy M. P. (2003): Mechanisms of glucocorticoid-induced Leydig cell apoptosis. *Mol. Cell Endocrinol.*, 199(1): 153–163.
- Guillemant J.; Taupin P.; Le H. and et al. (1999): Vitamin D status during puberty in French healthy male adolescents. *Osteoporos. Int.*, 10: 222–225.
- Guo H. Y.; Jiang L.; Ibrahim S. A.; Zhang L.; Zhang H.; Zhang M. and Ren F. Z. (2009): Orally administered lactoferrin preserves bone mass and microarchitecture in ovariectomized rats. *J. Nutr.*, 139(5): 958–964.
- Holick M.F. (2007): Vitamin D deficiency. *N. Engl. j. Med.*, 357: 266–281.
- Ilona K. S.; Maria Z.; Katarzyna R. and Lech S. (2012): Effects of thalidomide on the development of bone damage caused by prednisolone in rats. *Pharmacol. Reports*, 64(2): 386–395.
- Ima N. S. and Fakhrurazi H. (2002): Palm vitamin e protects bone against dexamethasone-induced osteoporosis in male rats. *Med. J. Malaysia*, 57(2): 136–144.
- Jacobs S.; Bootsma A. L.; Willems P. W. A.; Bär P. R. and Wokke J. H. J. (1996):

- Prednisone can protect against exercise-induced muscle damage. *J. Neurol.*, 243(5): 410–416.
- Kaczmarek E.; Gorna A. and Majewski P. (2004): Techniques of image analysis for quantitative immunohistochemistry. *Rocz. Akad. Med. Białymst.*, 49(1): 155–158.
- Kalu D. N.; Hardin R. R. and Cockerham R. (1984): Evaluation of the pathogenesis of skeletal changes in ovariectomized rats. *Endocrino.*, 115(2): 507–512.
- Kikuchi M.; Mizoroki S.; Kubo T.; Ohiwa Y.; Kubota M.; Yamada N.; Orino K.; Ohnami Y. and Watanabe K. (2003): Seminal plasma lactoferrin but not transferrin reflects gonadal function in dogs. *J. Vet. Med. Sci.*, 65(6): 679–684.
- Lane N.E. and Lukert B (1998): The science and therapy of glucocorticoid-induced bone loss. *Endocrinol. Metab. Clin. North. Am.*, 27:465–483.
- Lee G. S.; Choi K. C. and Jeung E. B. (2006): Glucocorticoids differentially regulate expression of duodenal and renal calbindin-D9k through glucocorticoid receptor-mediated pathway in mouse model. *Am. J. Physiol. Metab.*, 290(2): 299–307.
- Lin S.; Huang J.; Zheng L.; Liu Y.; Liu G.; Li N.; Wang K.; Zou L.; Wu T. and Qin L. et al. (2014): Glucocorticoid-induced osteoporosis in growing rats. *Calcif. Tissue. Int.*, 95(4): 362–373.
- Luiz H. de Gregório; Paulo G. S. L. ; Ana C. C. M. and Luis A. T. R. (2006): Glucocorticoid-Induced Osteoporosis. *Arq. Bras. Endocrinol. Metab.*, 50(4): 793–801.
- Luton J.P.; Thieblot P.; Valcke J.C.; Mahoudeau J.A. and Bricaire H. (1977): Reversible gonadotropin deficiency in male Cushing's disease. *J. Clin. Endocrinol. Metab.*, 45:488–495.
- McCarron D. A. and Heaney R. P. (2004): Estimated healthcare savings associated with adequate dairy food intake. *Am. J. Hypertens.*, 17(1): 88–97.
- Masson P. L. and Heremans J. F. (1971): Lactoferrin in milk from different species. *Comp. Biochem. Physiol. Part B Comp. Biochem.* 39(1): 119–129.
- Mateo L.; Nolla J. M.; Bonnin M. R.; Navarro M. A. and Roig-Escofet D. (1995): Sex hormone status and bone mineral density in men with rheumatoid arthritis. *J. Rheumatol.*, 22(8): 1455–1460.
- Mazziotti G.; Angeli A.; Bilezikian J. P.; Canalis E. and Giustina A. (2006): Glucocorticoid-induced osteoporosis: an update. *Trends Endocrinol. Metab.*, 17(4): 144–149.
- Naot D.; Grey A.; Reid I. R. and Cornish J. (2005): Lactoferrin--a novel bone growth factor. *Clin. Med. Res.*, 3(2): 93–101.
- Nobert WT. (1995): *Clinical Guide to Laboratory tests*. 3rd ed. Philadelphia. WB. Saunders, 268–273.
- Reid I. R. (1997): Glucocorticoid osteoporosis mechanisms and management. *Eur. J. Endocrinol.*, 137(3): 209–217.
- Reid I.R.; Ibbertson H.K.; France J.T. and Pybus J. (1985): Plasma testosterone concentrations in asthmatic men treated with glucocorticoids. *Br. Med. J. (Clin Res Ed)*. 291(6495): 574.
- Rhen T. and Cidlowski J. A. (2005): Anti inflammatory action of glucocorticoids new mechanisms for old drugs. *N. Engl. J. Med.*, 353(16): 1711–1723.
- Rubin M. R. and Bilezikian J. P. (2002): The role of parathyroid hormone in the pathogenesis of glucocorticoid-induced osteoporosis: a reexamination of the evidence. *J. Clin. Endocrinol. Metab.*, 87(9): 4033–4041.
- Sakakura M.; Takebe K. and Nakagawa S. (1975): Inhibition of luteinizing

- hormonesecretion induced by synthetic LRH by long-term treatment with glucocorticoids in human subjects. *J. Clin. Endocrinol. Metab.*, 40:774–779.
- Sass D. A.; Bowman A. R.; Yuan Z.; Ma Y.; Jee W. S. S. and Epstein S. (1997): Alendronate prevents cyclosporin A-induced osteopenia in the rat. *Bone*, 21(1): 65–70.
- Sayed A. A.; Soliman A. M.; Fahmy S. R. and Marzouk M. (2013): Antiosteoporotic effect of *Coelatura aegyptiaca* shell powder on ovariectomized rats. *African J. Pharm. Pharmacol.*, 7(34): 2406–2416.
- Shomali T. and Fakhrzad A. (2013): Niacin ameliorates hypercalciuria and hyperphosphaturia due to glucocorticoid administration in rats. *Am. J. Pharmacol. Toxicol.*, 8(2): 73–77.
- Tanaka S.; Nakamura K.; Takahashi N. and Suda T. (2005) Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL—RANK signaling system. *Immunol. Rev.*, 208: 30–49.
- Thakur R. S.; Toppo F. A.; Singour P. K.; Chaurasiya P. K. and Pawar R. S. (2013): Preclinical studies of various extracts of *Polyalthia longifolia* for the management of dexamethasone induced osteoporosis in rats. *Int. J. Pharm. Pharm. Sci.*, 5: 267–270.
- Yonemura K.1.; Hishida A.; Kimura M.; Watanabe T. and Kumagai H. (1999): Prednisolone induces an increase in serum calcium concentration: possible involvement of the kidney, the bone, and the intestine. *Calcif Tissue Int.*, 65(4):267-271.